---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-005733"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:21:04.482956+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M

## Summary
- Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).
- Net income Q4 $23.0M; full year $447.2M including $339.8M non-recurring deferred tax asset benefit.
- 2026 guidance: total global revenue $875-900M; BRIUMVI US net $825-850M; Q1 2026 target $185-190M.
- Completed $100M share repurchase (3.5M shares at avg $28.55); new $100M buyback authorized.
- Pipeline milestones: ENHANCE IV data mid-2026; subcutaneous ublituximab data year-end 2026/1Q 2027.

## SEC filing metadata
- accession: 0001437749-26-005733
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/0001437749-26-005733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774926005733/tgtx20251112_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-005733
- JSON: https://secwatch.observer/filing/0001437749-26-005733.json
- Plain text: https://secwatch.observer/filing/0001437749-26-005733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.